750 related articles for article (PubMed ID: 19572644)
1. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
2. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
6. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
[TBL] [Abstract][Full Text] [Related]
7. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
8. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
12. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
13. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
14. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
[TBL] [Abstract][Full Text] [Related]
15. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
[TBL] [Abstract][Full Text] [Related]
16. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
17. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.
Jahnke W; Grotzfeld RM; Pellé X; Strauss A; Fendrich G; Cowan-Jacob SW; Cotesta S; Fabbro D; Furet P; Mestan J; Marzinzik AL
J Am Chem Soc; 2010 May; 132(20):7043-8. PubMed ID: 20450175
[TBL] [Abstract][Full Text] [Related]
18. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
[TBL] [Abstract][Full Text] [Related]
20. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
